A multicenter trial of two dexamethasone regimens in ventilator- dependent premature infants

Lu Ann Papile, Jon E. Tyson, Barbara J. Stoll, Linda L. Wright, Edward F. Donovan, Charles R Bauer, Heidi Krause-Steinrauf, Joel Verter, Sheldon B. Korones, James A. Lemons, Avroy A. Fanaroff, David K. Stevenson, William Oh, Richard A. Ehrenkranz, Seetha Shankaran

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

Background: Ventilator-dependent premature infants are often treated with dexamethasone. However, the optimal timing of therapy is unknown. Methods: We compared the benefits and hazards of initiating dexamethasone therapy at two weeks of age and at four weeks of age in 371 ventilator- dependent very-low-birth-weight infants (501 to 1500 g) who had respiratory- index scores (mean airway pressure x the fraction of inspired oxygen) of ≤2.4 at two weeks of age. One hundred eighty-two infants received dexamethasone for two weeks followed by placebo for two weeks, and 189 infants received placebo for two weeks followed by either dexamethasone (those with a respiratory-index score of ≤2.4 on treatment day 14) or additional placebo for two weeks. Dexamethasone was given at a dose of 0.25 mg per kilogram of body weight twice daily intravenously or orally for five days, and the dose was then tapered. Results: The median time to ventilator independence was 36 days in the dexamethasone-placebo group and 37 days in the placebo-dexamethasone group. The incidences of chronic lung disease (defined as the need for oxygen supplementation at 36 weeks' postconceptional age) were 66 percent and 67 percent, respectively. Dexamethasone was associated with an increased incidence of nosocomial bacteremia (relative risk, 1.5; 95 percent confidence interval, 1.1 to 2.1) and hyperglycemia (relative risk, 1.9; 95 percent confidence interval, 1.2 to 3.0) in the dexamethasone-placebo group, elevated blood pressure (relative risk, 2.9; 95 percent confidence interval, 1.2 to 6.9) in the placebo-dexamethasone group, and diminished weight gain and head growth (P<0.001) in both groups. Conclusions: Treatment of ventilator-dependent premature infants with dexamethasone at two weeks of age is more hazardous and no more beneficial than treatment at four weeks of age.

Original languageEnglish
Pages (from-to)1112-1118
Number of pages7
JournalNew England Journal of Medicine
Volume338
Issue number16
DOIs
StatePublished - Apr 16 1998

Fingerprint

Mechanical Ventilators
Premature Infants
Dexamethasone
Multicenter Studies
Placebos
Confidence Intervals
Oxygen
Therapeutics
Very Low Birth Weight Infant
Incidence
Bacteremia
Hyperglycemia
Lung Diseases
Weight Gain
Chronic Disease
Head
Body Weight
Blood Pressure
Pressure

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Papile, L. A., Tyson, J. E., Stoll, B. J., Wright, L. L., Donovan, E. F., Bauer, C. R., ... Shankaran, S. (1998). A multicenter trial of two dexamethasone regimens in ventilator- dependent premature infants. New England Journal of Medicine, 338(16), 1112-1118. https://doi.org/10.1056/NEJM199804163381604

A multicenter trial of two dexamethasone regimens in ventilator- dependent premature infants. / Papile, Lu Ann; Tyson, Jon E.; Stoll, Barbara J.; Wright, Linda L.; Donovan, Edward F.; Bauer, Charles R; Krause-Steinrauf, Heidi; Verter, Joel; Korones, Sheldon B.; Lemons, James A.; Fanaroff, Avroy A.; Stevenson, David K.; Oh, William; Ehrenkranz, Richard A.; Shankaran, Seetha.

In: New England Journal of Medicine, Vol. 338, No. 16, 16.04.1998, p. 1112-1118.

Research output: Contribution to journalArticle

Papile, LA, Tyson, JE, Stoll, BJ, Wright, LL, Donovan, EF, Bauer, CR, Krause-Steinrauf, H, Verter, J, Korones, SB, Lemons, JA, Fanaroff, AA, Stevenson, DK, Oh, W, Ehrenkranz, RA & Shankaran, S 1998, 'A multicenter trial of two dexamethasone regimens in ventilator- dependent premature infants', New England Journal of Medicine, vol. 338, no. 16, pp. 1112-1118. https://doi.org/10.1056/NEJM199804163381604
Papile, Lu Ann ; Tyson, Jon E. ; Stoll, Barbara J. ; Wright, Linda L. ; Donovan, Edward F. ; Bauer, Charles R ; Krause-Steinrauf, Heidi ; Verter, Joel ; Korones, Sheldon B. ; Lemons, James A. ; Fanaroff, Avroy A. ; Stevenson, David K. ; Oh, William ; Ehrenkranz, Richard A. ; Shankaran, Seetha. / A multicenter trial of two dexamethasone regimens in ventilator- dependent premature infants. In: New England Journal of Medicine. 1998 ; Vol. 338, No. 16. pp. 1112-1118.
@article{857c14a146aa42fd8408a10dff20ae32,
title = "A multicenter trial of two dexamethasone regimens in ventilator- dependent premature infants",
abstract = "Background: Ventilator-dependent premature infants are often treated with dexamethasone. However, the optimal timing of therapy is unknown. Methods: We compared the benefits and hazards of initiating dexamethasone therapy at two weeks of age and at four weeks of age in 371 ventilator- dependent very-low-birth-weight infants (501 to 1500 g) who had respiratory- index scores (mean airway pressure x the fraction of inspired oxygen) of ≤2.4 at two weeks of age. One hundred eighty-two infants received dexamethasone for two weeks followed by placebo for two weeks, and 189 infants received placebo for two weeks followed by either dexamethasone (those with a respiratory-index score of ≤2.4 on treatment day 14) or additional placebo for two weeks. Dexamethasone was given at a dose of 0.25 mg per kilogram of body weight twice daily intravenously or orally for five days, and the dose was then tapered. Results: The median time to ventilator independence was 36 days in the dexamethasone-placebo group and 37 days in the placebo-dexamethasone group. The incidences of chronic lung disease (defined as the need for oxygen supplementation at 36 weeks' postconceptional age) were 66 percent and 67 percent, respectively. Dexamethasone was associated with an increased incidence of nosocomial bacteremia (relative risk, 1.5; 95 percent confidence interval, 1.1 to 2.1) and hyperglycemia (relative risk, 1.9; 95 percent confidence interval, 1.2 to 3.0) in the dexamethasone-placebo group, elevated blood pressure (relative risk, 2.9; 95 percent confidence interval, 1.2 to 6.9) in the placebo-dexamethasone group, and diminished weight gain and head growth (P<0.001) in both groups. Conclusions: Treatment of ventilator-dependent premature infants with dexamethasone at two weeks of age is more hazardous and no more beneficial than treatment at four weeks of age.",
author = "Papile, {Lu Ann} and Tyson, {Jon E.} and Stoll, {Barbara J.} and Wright, {Linda L.} and Donovan, {Edward F.} and Bauer, {Charles R} and Heidi Krause-Steinrauf and Joel Verter and Korones, {Sheldon B.} and Lemons, {James A.} and Fanaroff, {Avroy A.} and Stevenson, {David K.} and William Oh and Ehrenkranz, {Richard A.} and Seetha Shankaran",
year = "1998",
month = "4",
day = "16",
doi = "10.1056/NEJM199804163381604",
language = "English",
volume = "338",
pages = "1112--1118",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "16",

}

TY - JOUR

T1 - A multicenter trial of two dexamethasone regimens in ventilator- dependent premature infants

AU - Papile, Lu Ann

AU - Tyson, Jon E.

AU - Stoll, Barbara J.

AU - Wright, Linda L.

AU - Donovan, Edward F.

AU - Bauer, Charles R

AU - Krause-Steinrauf, Heidi

AU - Verter, Joel

AU - Korones, Sheldon B.

AU - Lemons, James A.

AU - Fanaroff, Avroy A.

AU - Stevenson, David K.

AU - Oh, William

AU - Ehrenkranz, Richard A.

AU - Shankaran, Seetha

PY - 1998/4/16

Y1 - 1998/4/16

N2 - Background: Ventilator-dependent premature infants are often treated with dexamethasone. However, the optimal timing of therapy is unknown. Methods: We compared the benefits and hazards of initiating dexamethasone therapy at two weeks of age and at four weeks of age in 371 ventilator- dependent very-low-birth-weight infants (501 to 1500 g) who had respiratory- index scores (mean airway pressure x the fraction of inspired oxygen) of ≤2.4 at two weeks of age. One hundred eighty-two infants received dexamethasone for two weeks followed by placebo for two weeks, and 189 infants received placebo for two weeks followed by either dexamethasone (those with a respiratory-index score of ≤2.4 on treatment day 14) or additional placebo for two weeks. Dexamethasone was given at a dose of 0.25 mg per kilogram of body weight twice daily intravenously or orally for five days, and the dose was then tapered. Results: The median time to ventilator independence was 36 days in the dexamethasone-placebo group and 37 days in the placebo-dexamethasone group. The incidences of chronic lung disease (defined as the need for oxygen supplementation at 36 weeks' postconceptional age) were 66 percent and 67 percent, respectively. Dexamethasone was associated with an increased incidence of nosocomial bacteremia (relative risk, 1.5; 95 percent confidence interval, 1.1 to 2.1) and hyperglycemia (relative risk, 1.9; 95 percent confidence interval, 1.2 to 3.0) in the dexamethasone-placebo group, elevated blood pressure (relative risk, 2.9; 95 percent confidence interval, 1.2 to 6.9) in the placebo-dexamethasone group, and diminished weight gain and head growth (P<0.001) in both groups. Conclusions: Treatment of ventilator-dependent premature infants with dexamethasone at two weeks of age is more hazardous and no more beneficial than treatment at four weeks of age.

AB - Background: Ventilator-dependent premature infants are often treated with dexamethasone. However, the optimal timing of therapy is unknown. Methods: We compared the benefits and hazards of initiating dexamethasone therapy at two weeks of age and at four weeks of age in 371 ventilator- dependent very-low-birth-weight infants (501 to 1500 g) who had respiratory- index scores (mean airway pressure x the fraction of inspired oxygen) of ≤2.4 at two weeks of age. One hundred eighty-two infants received dexamethasone for two weeks followed by placebo for two weeks, and 189 infants received placebo for two weeks followed by either dexamethasone (those with a respiratory-index score of ≤2.4 on treatment day 14) or additional placebo for two weeks. Dexamethasone was given at a dose of 0.25 mg per kilogram of body weight twice daily intravenously or orally for five days, and the dose was then tapered. Results: The median time to ventilator independence was 36 days in the dexamethasone-placebo group and 37 days in the placebo-dexamethasone group. The incidences of chronic lung disease (defined as the need for oxygen supplementation at 36 weeks' postconceptional age) were 66 percent and 67 percent, respectively. Dexamethasone was associated with an increased incidence of nosocomial bacteremia (relative risk, 1.5; 95 percent confidence interval, 1.1 to 2.1) and hyperglycemia (relative risk, 1.9; 95 percent confidence interval, 1.2 to 3.0) in the dexamethasone-placebo group, elevated blood pressure (relative risk, 2.9; 95 percent confidence interval, 1.2 to 6.9) in the placebo-dexamethasone group, and diminished weight gain and head growth (P<0.001) in both groups. Conclusions: Treatment of ventilator-dependent premature infants with dexamethasone at two weeks of age is more hazardous and no more beneficial than treatment at four weeks of age.

UR - http://www.scopus.com/inward/record.url?scp=0032537074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032537074&partnerID=8YFLogxK

U2 - 10.1056/NEJM199804163381604

DO - 10.1056/NEJM199804163381604

M3 - Article

C2 - 9545359

AN - SCOPUS:0032537074

VL - 338

SP - 1112

EP - 1118

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 16

ER -